Kazia Therapeutics Ltd
KZIA8.470USD
+0.290+3.54%
取引時間 （ET）15分遅れの株価
8.19M時価総額
--直近12ヶ月PER
詳細情報 Kazia Therapeutics Ltd 企業名
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
企業情報
企業コードKZIA
会社名Kazia Therapeutics Ltd
上場日Sep 01, 1994
最高経営責任者「CEO」Dr. John E. Friend, M.D.
従業員数- -
証券種類Depository Receipt
決算期末Sep 01
本社所在地Three International Towers Level 24,
都市SYDNEY
証券取引所NASDAQ Capital Market Consolidated
国Australia
郵便番号2000
電話番号1161298780088
ウェブサイトhttps://www.kaziatherapeutics.com/
企業コードKZIA
上場日Sep 01, 1994
最高経営責任者「CEO」Dr. John E. Friend, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
収益内訳
通貨: USD更新時刻: Tue, Mar 4
通貨: USD更新時刻: Tue, Mar 4
FY2022
FY2021
データなし
地域別USD
会社名
収益
比率
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
事業別
地域別
データなし
株主
更新時刻: Sun, Jun 15
更新時刻: Sun, Jun 15
株主統計
種類
株主統計
株主統計
比率
Chernett (Jorey)
8.48%
Dauntless Investment Group, LLC
4.98%
Barclays Capital Inc.
1.48%
UBS Financial Services, Inc.
0.32%
MAI Capital Management, LLC
0.05%
Other
84.69%
株主統計
株主統計
比率
Chernett (Jorey)
8.48%
Dauntless Investment Group, LLC
4.98%
Barclays Capital Inc.
1.48%
UBS Financial Services, Inc.
0.32%
MAI Capital Management, LLC
0.05%
Other
84.69%
種類
株主統計
比率
Individual Investor
8.48%
Investment Advisor
5.34%
Research Firm
1.48%
Investment Advisor/Hedge Fund
0.06%
Hedge Fund
0.01%
Other
84.62%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
37
248.92K
15.38%
+203.79K
2025Q1
39
31.11K
2.29%
-13.78K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
2023Q1
33
27.66K
1.21%
-46.04K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Chernett (Jorey)
137.20K
10.09%
+137.20K
--
Jun 11, 2025
Dauntless Investment Group, LLC
80.62K
5.93%
+80.62K
--
Jun 11, 2025
Barclays Capital Inc.
24.00K
1.77%
+19.20K
+400.00%
Mar 31, 2025
UBS Financial Services, Inc.
5.26K
0.39%
+4.16K
+377.04%
Mar 31, 2025
MAI Capital Management, LLC
771.00
0.06%
-4.80K
-86.15%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
382.00
0.03%
+271.00
+244.14%
Mar 31, 2025
GAMMA Investing LLC
265.00
0.02%
+265.00
--
Mar 31, 2025
Armistice Capital LLC
219.00
0.02%
+219.00
--
Sep 30, 2024
Arax Advisory Partners
200.00
0.01%
+200.00
--
Mar 31, 2025
Osaic Holdings, Inc.
10.00
0%
+8.00
+400.00%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
日付
種類
比率
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
